FundedIQ
Biotechnology

ADEL

The company is a spin-off from Asan Medical Center, University of Ulsan University, with a primary objective of developing therapeutic and diagnostic agents for neurological diseases, particularly Alzheimer's disease. In 2016, the company took significant steps toward formalizing its presence in the market by completing its incorporation and business registration processes. The year 2017 proved to be a milestone for the company as it obtained certification as a corporate-affiliated research institute, solidifying its position as a reputable research-driven organization. Additionally, it garnered recognition as a leading university start-up by the Ministry of SMEs and Startups, further boosting its credibility and potential for growth. The company has collaborated with Oscotech Co., Ltd. and partnered with various investors, including Kite Entrepreneurship Foundation, Stone Bridge Ventures Co., Ltd., Korea Development Bank, and Stick Ventures Co., Ltd., to jointly develop their projects.

www.adelpharm.com Seoul, South Korea 11-50 employees
Total raised
$2.4M
Rounds
1
Latest
Series Unknown
Jun 2026

The company is a spin-off from Asan Medical Center, University of Ulsan University, with a primary objective of developing therapeutic and diagnostic agents for neurological diseases, particularly Alzheimer's disease. In 2016, the company took significant steps toward formalizing its presence in the market by completing its incorporation and business registration processes. The year 2017 proved to be a milestone for the company as it obtained certification as a corporate-affiliated research institute, solidifying its position as a reputable research-driven organization. Additionally, it garnered recognition as a leading university start-up by the Ministry of SMEs and Startups, further boosting its credibility and potential for growth. The company has collaborated with Oscotech Co., Ltd. and partnered with various investors, including Kite Entrepreneurship Foundation, Stone Bridge Ventures Co., Ltd., Korea Development Bank, and Stick Ventures Co., Ltd., to jointly develop their projects.

ADEL has raised $2.4M across 1 round. Its most recent round was a Series Unknown of $2.4M in Jun 2026. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Jun 11, 2026
Series Unknown
$2.4M

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

ADEL is featured in

Similar companies

LegoChem Biosciences

Lego Chem Bioscience , a company created by people with dreams and enthusiasm for global new drug development, will open up new horizons in Korean new drug development based on systematic drug development system and core technology.

Series Unknown $214M
April Bio

April Bio is a drug development company that develops antibodies and long-acting biologics.

Series Unknown $124M
LabGenomics

LabGenomics is a healthcare company specialized in molecular diagnostics.

Series Unknown $13.0M
Cureverse

Galaxy operates a pharmaceutical research and development company for the treatment of encephalopathy and oncology diseases. The company focuses on creating remedies for challenging brain conditions like dementia, thereby assisting healthcare professionals in enhancing human well-being and overall quality of life.

Series Unknown $990k
Spark Biopharma

SPARK BioPharma Co., Ltd. was established in Seoul National University in January 2016 based on the unique drug molecule diversity technology, the image-based screening technology using the unique fluorescent skeleton probe, and the target protein identification technology in the initial drug development stage. We are currently exploring and developing new drug candidates using these three core technologies, and we will continue to accelerate the development of new drugs and increase the success rate through strategic cooperation research with domestic and overseas research institutes and pharmaceutical institutions. '

Series Unknown $21.4M
3billion

3billion was founded with the goal of ending the diagnostic odyssey of rare disease patients through comprehensive genetic testing. It has reduced the amount of time and cost that was previously required for genome interpretation by using bioinformatics and machine learning technology, making genome-scale rare disease genetic testing affordable for patients in need. The company was established in 2016 and is headquartered in Seoul, South Korea.

Series Unknown $11.8M
Shaperon

Shaperon is a clinical-stage biotech company that develops inflammasome inhibitors.

Series Unknown $5.8M
SN BioScience

SN BioScience provide nano-formulation screening services for small molecule, oligonucleotide (siRNA, DNA), peptide and protein to deliver in the form of nano-micelle, nanoparticle or liposome. Their proprietary “double core-shell technology” and pool of acceptable lipids and polymers could help your research that having difficulties in solubility or delivery.

Series Unknown $9.3M
Beeline Medicines

Beeline Medicines is a biotechnology company that identifies and provides precise treatments to autoimmune inflammatory disorders.

Series A $126M
Tenon Medical

Tenon Medical, a biotech firm specializing in enhancing surgical solutions for the SI joint, was established in 2012 in Morgan Hill, California.

Series Unknown $4.2M
Biodexa Pharmaceuticals

Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech's strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions.

Series Unknown $3.5M
Collplant

CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also develops and commercializes tissue repair products for orthobiologics. The company's products are based on the rhCollagen that is produced with CollPlant’s proprietary plant-based genetic engineering technology. The rhCollagen BioInk is ideal for 3D bioprinting of tissues and organs, and the unique Vergenix line of rhCollagen products contains a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote rapid optimal healing of acute and chronic wounds. CollPlant is headquartered in Rehovot, Israel.

Series Unknown $2.6M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.